VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma Patients
pharmaceutical investing VBI Vaccines Announces Dosing of First Patient in Phase 1/2a Clinical Study of VBI-1901
pharmaceutical investing VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction
Premier American Uranium Reports Results Following Annual General and Special Meeting of Shareholders
Nuvau Winter Drilling at Thundermine Returns 5.28 g/t Au over 6.1 m, Including 7.22 g/t Au over 3.1 m
